Identification and prognostic analysis of metabolic genes associated with TP53 mutation in multiple myeloma

TP53 gene mutation is crucial in determining the prognosis of Multiple Myeloma (MM) patients. Understanding metabolic genes linked to TP53 mutation is vital for developing targeted therapies for these patients. We analyzed The Cancer Genome Atlas (TCGA) dataset to identify genes related to TP53 muta...

Full description

Saved in:
Bibliographic Details
Published in:Hematology (Luxembourg) 2024-12, Vol.29 (1), p.2377850
Main Authors: Tang, Xiaoyan, Chen, Yongping
Format: Article
Language:English
Subjects:
bioinformatics
Female
Gene Expression Regulation, Neoplastic
Humans
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - genetics
Multiple Myeloma - mortality
Mutation
Prognosis
Ribonucleoside Diphosphate Reductase - genetics
RRM2
TP53
Tumor Suppressor Protein p53 - genetics
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:TP53 gene mutation is crucial in determining the prognosis of Multiple Myeloma (MM) patients. Understanding metabolic genes linked to TP53 mutation is vital for developing targeted therapies for these patients. We analyzed The Cancer Genome Atlas (TCGA) dataset to identify genes related to TP53 mutation and metabolism. Using univariate Cox regression and protein-protein interaction (PPI) analysis, we identified key genes. We categorized patients into high and low metabolism groups via non-negative matrix factorization (NMF) clustering, which led to the discovery of relevant differential genes. Integrating these with genes from the Gene Expression Omnibus (GEO) datasets and PPI interactions, we pinpointed crucial metabolic genes associated with TP53 mutation in MM. Additionally, we conducted prognostic analyses involving survival curves and receiver operating characteristic (ROC) charts. Our study reveals that the metabolic gene ribonucleotide reductase M2 (RRM2), linked to TP53 mutation, correlates positively with the International Staging System (ISS) stage in MM patients and is an independent prognostic risk factor. In the TCGA dataset, among the 767 patients, the 35 MM patients with TP53 mutation generally had poor survival outcomes. Specifically, the patients with both TP53 mutation and high RRM2 expression had a 2-year survival rate of only 38.87%, whereas those with normal TP53 function and low RRM2 expression had a 2-year survival rate of 86.31% (  
ISSN:1607-8454
1607-8454
DOI:10.1080/16078454.2024.2377850